Últimas noticias sobre LeddarTech Holdings (NASDAQ:LDTC) Bolsa

LeddarTech Holdings

LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation. The company generates the majority of its revenue from France, Canada, and the United states.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

TRAW

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

LeddarTech Holdings Inc

Guidance

SOUN

SoundHound AI Filed Non-Timely 10-K With SEC, Reports Continued Material Weaknesses As Of Dec 31, 2024

WIIM

ESPR

Esperion Therapeutics shares are trading higher after the company reported better than expected Q4 FY24 earnings.

Citigroup analyst Joanne Wuensch downgrades Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) from Buy to Neutral and lowers the price target from $35 to $24.

Downgrades

Price Target

Analyst Ratings

TNDM

Citigroup Downgrades Tandem Diabetes Care to Neutral, Lowers Price Target to $24

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE.jpeg" alt="" class="wp-image-7077" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The dental products and materials maker derives 70% of its revenue from China, but plans to use IPO proceeds for a new production base in Indonesia
Key Takeaways:
<ul>
<li>Huge Dental has applied for a Hong Kong IPO, reporting a net profit of 77.7 million yuan on 300 million yuan in revenue in the first three quarters of 2024</li>
<li>The dental products supplier plans to use proceeds from the listing to build a factory in Indonesia as a base for global expansion</li>
</ul>
If they frown on you in one market, then maybe they'll smile in another.
That seems to be the attitude of dental products maker&nbsp;Huge Dental Ltd., which has given up on plans to list on China's domestic A-share markets in Shanghai and Shenzhen after efforts over the past decade went nowhere. Now, the company is hoping for a warmer greeting in Hong Kong with its&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107132/documents/sehk25021900956.pdf">new application</a>&nbsp;to list on the city's the stock exchange filed late last month.
Huge Dental wasn't completely out of luck when it came to Chinese Mainland listings. The company once listed on the Beijing-based over-the-country style National Equities Exchange and Quotations (NEEQ) board as early as April 2015. But it delisted two years later amid thin trading.
It aimed to graduate to the majors with its July 2017 application to list on Shenzhen's Nasdaq-style ChiNext board for growth companies but terminated that application two years later. Not one to give up so easily, it tried again in 2019, this time on Shanghai's then-newly launched STAR market, also for growth companies, but failed once more.
Those repeated setbacks never wiped the smile from Huge Dental's face, as it hopes its third try at the big leagues will be the charm. It could very well have better luck this outing, as Hong Kong has typically been far friendlier to this type of consumer-style listing, unlike the ChiNext and STAR markets that prefer sexier growth sectors like tech and new energy.
Huge Dental's listing document shows it was founded in 2006 by Song Xin, now 52. Its main business is divided into three categories: dental clinical products, like impression-taking materials and resin adhesive materials; dental laboratory products, which mainly refers to denture restoration materials; and dental digital products. The vast majority of its revenue, around 97%, comes from the first two categories.
<h4 class="wp-block-heading">Improving margins</h4>
Huge Dental is China's largest manufacturer of elastomeric impression materials and synthetic resin teeth, based on revenue in 2023, according to third-party market data in the company's listing document. The broader dental industry has been feasting for the last decade on a new Chinese middle class that can now afford such small luxuries as dentures and other forms of synthetic teeth.
As the sector expanded, Huge Dental's revenue grew 28% from 280 million yuan ($38.6 million) in 2022 to 358 million yuan in 2023. Its revenue continued growing last year, though at a slower pace, rising 14% year-on-year to 304 million yuan in the first nine months of 2024. Its net profit similarly rose 38% from 64 million yuan in 2022 to 88.4 million yuan in 2023. The growth continued at a slower rate last year, up 6.6% in the first nine months of 2024 to 77.7 million yuan. Perhaps most importantly, the company's gross margin has also climbed steadily from 54.9% in 2022 to 59.2% in the first nine months of last year.
Huge Dental sells its products in more than 60 countries and regions, though nearly 70% of its revenue comes from its home China market. Its other major markets are Europe, accounting for about 12% of revenue, and North America, at about 10%. It plans to use IPO proceeds to buy land in Indonesia, where it wants to construct a new factory that will serve as a strategic base to further its global expansion.
<h4 class="wp-block-heading">National policy dividend</h4>
Huge Dental is lucky to be selling into the right environment, especially as many consumer sectors suffer in China's economic slowdown. On a global scale, a worldwide aging population and growing awareness of dental health have caused demand for dental medical supplies to rise sharply, valued at $37.8 billion in 2019 and expected to reach $83.7 billion in 2030, according to the listing document. China's market is especially buoyant, rising from 43.4 billion yuan in 2019 to 60.7 billion yuan in 2023, and expected to grow 15.5% annually from then to reach 166.7 billion yuan in 2030.
Government policy support has helped to boost the industry in China, with oral health recognized as a priority in the country's "Healthy China 2030" initiative. The government has encouraged development of domestically made, self-developed dental materials to nurture local brands and ween the country off imported products commonly used in the past. Huge Dental is a big beneficiary of such policies.
As Chinese brands begin to rise, they have lured away customers who traditionally bought imported products by offering prices that are generally 30% to 50% lower than those for the imports. At the same time, the domestic names are also rapidly closing the divide with foreign products in terms of quality.
A case in point is the recent unseating of U.S.-based&nbsp;Invisalign&nbsp;(ALGN.US), king of the invisible braces market, by homegrown&nbsp;Angelalign&nbsp;(6699.HK) in the Chinese market. In 2021, Angelalign's 41.1% share of China's invisible braces market made it king of the hill ahead of Invisalign, which has been in second place ever since.
<h4 class="wp-block-heading">Fierce competition</h4>
China is currently Huge Dental's mainstay, but that doesn't mean the domestic competition isn't fierce, both from emerging local and well-known global brands. Given skepticism about domestic technologies in general, Huge Dental may need to give more clinical data about its product performance and disclose more information about its patents to win over foreign investors.
To stand out from the crowd, the company must show it is constantly working to improve its products to stay ahead of rivals. In that regard, its digital dental products business might have a greater role to play in executing such a strategy. While that part of its business currently accounts for only 0.8% of its revenue, Huge Dental is planning to step up its development of intraoral scanners, 3D printers, 3D printing materials and AI-driven diagnostic tools to provide dentists with better diagnostic and treatment solutions.
Of the two major dental stocks currently listed in Hong Kong, Angelalign's price-to-earnings (P/E) ratio of 184 times is inflated by its small profit, making it an inappropriate reference. A more suitable comparison is&nbsp;Modern Dental&nbsp;(3600.HK), whose P/E stands at just 9 times. Huge Dental may be more conservative in the valuation it seeks since it's smaller than Modern Dental and could otherwise face difficulties attracting investors.
While an attractive valuation could win over investors to its IPO, the company will need a more compelling story to keep such investors over the longer run. Such a story could show the potential for "high-quality domestic substitution + digitalized products," as two major growth drivers headed into the future.

Asia

Equities

Health Care

China's Huge Dental Files For Hong Kong IPO

On Tuesday, <a target="_blank" href="https://www.benzinga.com/25/03/44084767/taiwan-semiconductor-weighs-100-billion-us-investment-as-chip-war-heats-up" rel="noreferrer noopener">contract chipmaker</a> Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) announced plans to invest an additional $100 billion in advanced semiconductor manufacturing in the U.S.
Building on the company&#8217;s ongoing $65 billion investment in its advanced semiconductor manufacturing operations in Phoenix, Arizona, Taiwan Semiconductor&#8217;s total investment in the U.S. will likely reach $165 billion. The expansion includes plans for three new fabrication plants, two advanced packaging facilities, and a significant R&amp;D team center.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44087877/intel-stock-surges-as-nvidia-broadcom-test-18a-chips-amd-shows-interest" rel="noreferrer noopener">Intel Gains Traction With 18A Process As Nvidia, Broadcom Consider Manufacturing Contracts</a>
The contract chipmaker expects to create hundreds of billions of dollars in semiconductor value for AI and other cutting-edge applications. The expanded investment will likely support 40,000 construction jobs over the next four years and create tens of thousands of high-paying, high-tech jobs in advanced chip manufacturing and R&amp;D.
It will likely drive over $200 billion of indirect economic output in Arizona and across the U.S. in the next decade, the company said.
Taiwan Semiconductor&#8217;s Arizona fab currently employs more than 3,000 people on 1,100 acres of land in Arizona. The site has been in volume production since late 2024.
U.S. President Donald Trump has been a <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/44013241/taiwan-semiconductor-faces-government-scrutiny-on-overseas-ventures-amid-intel-stake-rumors" rel="noreferrer noopener">critic of Taiwan</a> since his presidential campaign days for accusing them of allegedly stealing American semiconductor business. He promised action against the country and threatened retaliatory tariffs because of Taiwan&#8217;s large trade surplus with the U.S.
IDC expects the <a target="_blank" href="https://www.benzinga.com/24/12/42480928/taiwan-semi-set-to-command-67-foundry-market-share-idc" rel="noreferrer noopener">Taiwanese contract chipmaker</a> to command a 67% share of the global foundry market in 2025, up 300 bps year over year.
Separate reports indicated the U.S. government canvassing Taiwan Semiconductor to help bail out Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) out of its woes <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/44013241/taiwan-semiconductor-faces-government-scrutiny-on-overseas-ventures-amid-intel-stake-rumors" rel="noreferrer noopener">via strategic acquisition</a>.
Meanwhile, Big Tech giants remain&nbsp;aggressively invested in&nbsp;their AI ambitions.&nbsp;Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), a key Taiwan Semiconductor client, committed over $500 billion to AI and advanced manufacturing.
Price Action:&nbsp;TSM stock traded higher by 1.48% to $175.53 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44088403/amazon-web-services-bets-big-on-india-with-82-billion-cloud-investment" target="_blank" rel="noreferrer noopener">Amazon Web Services Bets Big On India with $8.2 Billion Cloud Investment</a></li>
</ul>
Photo by wakamatsu.h via Shutterstock

Tech

AAPL

INTC

Taiwan Semiconductor Doubles Down On US Chipmaking, Plans $165 Billion Investment

Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are trading lower premarket on Tuesday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44096388/plug-power-announces-continued-cash-flow-improvement-and-progress-on-path-to-profitability" rel="noreferrer noopener">reported fourth-quarter&nbsp;results</a>.
The company reported&nbsp;revenue of&nbsp;$191.5 million, missing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst&nbsp;estimates&nbsp;of&nbsp;$263.2 million</a>.
The company reached a pivotal milestone in electrolyzer deployments, expanded its hydrogen network, and enhanced the utilization of its manufacturing facilities.
Electrolyzer revenue escalated 583% Y/Y, aided by 5-MW system sales and a large-scale order deployment.
Customer warrant charges stood at $22.7 million, impacted by updated forecasts and the timing of customer programs.
In the fourth quarter, operating cash flow improved 46% year over year (Y/Y), led by margin expansion and better working capital efficiency.
Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/technicals/25/03/44088446/plug-power-stock-nears-oversold-territory-will-q4-earnings-be-the-turning-point" rel="noreferrer noopener">Plug Power Stock Nears Oversold Territory: Will Q4 Earnings Be The Turning Point?</a>
In the quarter, the company reported a gross margin loss of 122%, reflecting a strategic deceleration in investments for mobility, high-power stationary applications, and product development.
Despite the significant improvement in cash burn, the company said it determined that the strategic actions to temper the investment pace on certain platforms, coupled with the fact that certain markets are developing slower than expected, collectively resulted in accounting conclusions to record varied non-cash impairments of certain long-lived and intangible assets.
The company recorded $971.3 million in non-cash charges for asset impairments and bad debt provisions in the fourth quarter on strategic shifts and market demand pushouts.
These impairments are expected to lower future depreciation and amortization by an estimated <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$55 million – $60 million in 2025</a>.
Plug CEO Andy Marsh said, &#8221;While we made great strides in improving cash flows in 2024, it is clear based on market dynamics that we have to make additional strides, therefore we are initiating Project Quantum Leap to further position Plug for success in the near and long term by continuing to leverage the platforms we have built while further optimizing the Company.&#8221;
Plug Power expects Project Quantum Leap to reduce annual expenses in the range of $150 million to $200 million.
These measures are expected to include additional reductions in the workforce over the coming weeks, furthering its rooftop facility consolidations, additional reductions in discretionary spending, additional reduction and leveraging of inventory, and limiting capital expenditures to near-term critical requirements.
The company expects that taking these actions will further improve margins and cash flows and accelerate the path to profitability.&nbsp;
As of 2024, unrestricted cash stood at over $200 million. The company expects cash burn in 2025 to continue to significantly improve.
Investors can gain exposure to the stock via&nbsp;ProShares S&amp;P&nbsp;Kensho Cleantech ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTEX#NYSE">CTEX</a>).&nbsp;
Price Action: PLUG shares are down 2.00% at $1.47 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44042800/plug-power-ties-executive-compensation-plan-to-stock-performance" target="_blank" rel="noreferrer noopener">Plug Power&#8217;s High-Stakes Move: Executives Can Take Up To 75% Of Pay In Company Stock</a></li>
</ul>
Photo via Shutterstock.

Earnings

Small Cap

CTEX

PLUG

Plug Power Tightens Its Belt: Plans Massive Cost Cuts & Cash Burn Control In New Strategy

Citigroup analyst Joanne Wuensch upgrades Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Neutral to Buy and raises the price target from $92 to $107.

Upgrades

Citigroup Upgrades Medtronic to Buy, Raises Price Target to $107

On Monday, March 3rd, U.S. markets closed sharply lower after Trump announced 25% tariffs on Canada and Mexico, with the S&amp;P 500 seeing its worst drop since December. Stocks had already slipped after an ISM survey showed declining manufacturing PMI. Investors, expecting a delay, reacted as markets priced in the tariff impact.
Related: <a target="_blank" href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying" rel="noreferrer noopener">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a>
The New Orders Index contracted to 48.6%, while the Production Index expanded to 50.7%. Prices surged to 62.4% due to tariff-driven costs. Employment fell to 47.6%, indicating workforce reductions. New Export Orders dipped to 51.4%, while Imports rose to 52.6%.
Most S&amp;P 500 sectors fell, led by tech, energy, and consumer discretionary stocks, while real estate and consumer staples gained.
The Dow Jones Industrial Average fell 1.348% to close at 43,191.24, the S&amp;P 500 declined 1.76% to 5,849.72, and the Nasdaq Composite was down 2.64% to 18,350.19.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 declined 1.34% to 37,318.50, led by losses in the Fishery, Transportation Equipment, and Chemical sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 slid 0.58%, closing at 8,198.10, led by losses in the Energy, Utilities and Resources sectors.</li>
<li>India&#8217;s Nifty 50 was down 0.18% to 22,080.30, led by losses in the Auto, Technology, and Fast-Moving Consumer Goods sectors, while the Nifty 500 gained 0.06% to 19,909.40.</li>
<li>China&#8217;s Shanghai Composite gained 0.22% to 3,324.21, and the Shanghai Shenzhen CSI 300 fell 0.08% to 3,885.22.</li>
<li>Hong Kong&#8217;s Hang Seng fell 0.28%, ending the session at 22,941.77.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was down 1.85%.</li>
<li>Germany&#8217;s DAX declined 1.98%.</li>
<li>France&#8217;s CAC fell 1.14%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.29%</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.80% at $67.82/bbl, and Brent was down 1.10% at $70.82/bbl.</li>
<li>Oil prices fell as OPEC+ confirmed an April output hike, and U.S. tariffs on Canada, Mexico, and China took effect, prompting retaliatory measures. Trump&#8217;s pause on Ukraine aid also raised speculation of potential Russian sanctions relief, further pressuring crude markets.</li>
<li>Natural Gas declined 0.46% to $4.102.</li>
<li>Gold was trading higher by 0.80% at $2,924.29, Silver was up 0.47% to $32.465, and Copper slipped 1.62% to $4.5322.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were down 0.15%, S&amp;P 500 futures fell 0.16% and Nasdaq 100 futures slid 0.04%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index slipped 0.26% to 106.27, USD/JPY was down 0.43% to 148.85, and USD/AUD rose 0.02% to 1.6069.</li>
<li>The U.S. dollar fell Tuesday amid trade tensions and economic slowdown fears despite new tariffs on Canada, Mexico, and China.</li>
<li>Trump&#8217;s <a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets" target="_blank" rel="noreferrer noopener">25% tariffs</a> on Canada and Mexico and increased duties on Chinese goods took effect, triggering retaliatory measures. China imposed new tariffs and restrictions, while Canada and Mexico planned countermeasures. Markets reacted negatively, fearing economic disruptions, rising costs, and recession risks. Trump&#8217;s aggressive trade policies continue reshaping global commerce.</li>
</ul>
Photo via Shutterstock

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Decline; Oil Falls As OPEC+ Confirms Output Hike - Global Markets Today While US Slept

Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.52) by 5.77 percent. This is a 885.71 percent decrease over earnings of $0.07 per share from the same period last year. The company reported $(665.00 thousand) in sales this quarter. This is a 100.61 percent decrease over sales of $108.45 million the same period last year.

Earnings Misses

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharma Q4 EPS $(0.55) Misses $(0.52) Estimate

Citigroup analyst Patrick Donnelly downgrades Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) from Buy to Neutral and maintains the price target from $185 to $185.

Citigroup Downgrades Quest Diagnostics to Neutral, Maintains Price Target to $185

U.S. stock futures declined on Tuesday following the worst trading day of 2025 on Monday. Futures of all benchmark indices fell in premarket trading except Nasdaq 100.
Investor anxiety over tariffs loomed as the March 4 deadline for tariff imposition on Mexico and Canada neared. President Donald Trump indicated on Monday that there was &#8220;no room left&#8221; for tariff negotiations with Canada and Mexico. He will be addressing the Congress today, which is expected to give further clarity on tariffs and other policies.
Meanwhile, the Treasury yields slipped further on Tuesday. The 10-year Treasury yield stood at 4.16%, while the two-year yield was at 3.93%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 91% chance that the Federal Reserve will keep interest rates unchanged for the March meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.03%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.33%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Tuesday. SPY was up 0.046% to $584.04, and QQQ advanced 0.23% to $498.20, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Real estate, consumer staples, health care and utilities were the only sectors that advanced on Monday. The market witnessed the second worst trading day of March ever as information technology, energy, consumer discretionary, and materials led the decline.
On the economic front, February&#8217;s S&amp;P final U.S. manufacturing PMI came in at 52.7 as compared to the preliminary reading of 51.6. This was at a 32-month high signaling an improvement in the health of the manufacturing sector.
The ISM Manufacturing PMI rose to 50.3 in February 2025, indicating a second consecutive month of slight expansion for U.S. manufacturing. In January, private residential construction spending decreased by 0.4%, with notable reductions in both multifamily construction and home improvement expenditures.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.64%</td>
<td>18,350.19</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.76%</td>
<td>5,849.72</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.48%</td>
<td>43,191.24 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-2.81%</td>
<td>2,102.24</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Bearish investor sentiment surged to a near-historic 60.6% in late February, the highest in 30 months, signaling a potential contrarian buying opportunity.
Ryan Detrick of Carson Research noted that historically, stocks average a 28% gain a year after such high bearish readings, although exceptions like 2008 exist. He observed that even at a 55% bearish threshold, returns are generally strong.
Detrick suggests that barring a financial crisis, which he deems unlikely, "investors willing to stay strong and not panic sell" could see significant gains, with the S&amp;P 500 averaging nearly 13% higher in six months and 18% in a year following similar sentiment spikes.
Talking about the effects of Trump's policies on the market, the chairman and CIO of Navellier &amp; Associates, Louis Navellier said, "The volatility is certainly being fed by Trump 2.0 moves, with tariffs scheduled to be launched soon,"
Economist Jeremy Siegel, on the other hand, stated that investors are taking profits on high-flying tech and reconsidering value stocks. However, he added that slowing economic growth could hamper the value stocks as well. "In a weakening economy, all stocks face challenges, though dividend-paying and more defensive equities may benefit from lower interest rates," he added.
See Also:<a href="https://www.benzinga.com/money/how-to-trade-futures"> How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Tuesday:
<ul>
<li>New York Fed President John Williams will speak at 2:20 p.m. ET, whereas, Richmond Fed President Tom Barkin will speak at an undetermined time.</li>
</ul>
Stocks In Focus:
<ul>
<li>Crowdstrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) was up 0.34% in the premarket on Tuesday ahead of its earnings, which will be released after the opening bell. Analysts expect it to report earnings of 86 cents per share on revenue of $1,034.3 million.</li>
</ul>
<ul>
<li>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) advanced 0.39% as Wall Street expects it to report quarterly earnings of $2.25 per share on revenue of $30.85 billion before the opening bell.</li>
</ul>
<ul>
<li>Green Dot Corporation. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) jumped 15.50% as it surpassed fourth-quarter earnings and revenue expectations and appointed Kim Olson as the new CFO.</li>
</ul>
<ul>
<li>Walgreens Boots Alliance Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) climbed 6.14% as private equity firm Sycamore Partners could take the company private by Thursday this week, reported WSJ.</li>
</ul>
<ul>
<li>Sacks Parente Golf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPGC#NASDAQ">SPGC</a>) slumped 37.16% after it announced a 1-for-30 reverse stock split.</li>
</ul>
<ul>
<li>Tenaya Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) dropped 25.02% as the company announced plans for a public offering of units, including common stock and two warrant series, plus pre-funded units with immediately exercisable warrants.</li>
</ul>
<ul>
<li>Sphere Entertainment Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) was 0.16% lower as it missed the earnings estimates.</li>
</ul>
<ul>
<li>Biodesix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) surged 18.65% after reporting a total revenue reaching $71.3 million, up 45% year-on-year.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.11% to hover around $67.61 per barrel.
The gold spot index was up by 0.90% to $2,919.13 per ounce. Its last record high was at $2,956.37 per ounce. The Dollar Index was down 0.46% at the 106.254 level.
Asian markets were lower on Tuesday as India's S&amp;P BSE Sensex, China's CSI 300, South Korea's Kospi, Japan's Nikkei 225, Australia's ASX 200, and Hong Kong's Hang Seng index declined. European markets were also lower in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44070799/mark-cuban-supports-trumps-new-gold-card-scheme-if-sold-to-corporations-for-employee-citizenship-have-a-look-at-the-listed-companies-with-most-number-of-immigrants">Mark Cuban Supports Trump&#8217;s New &#8216;Gold Card&#8217; Scheme If Sold To Corporations For Employee Citizenship: Here&#8217;re The Listed-Companies With Most Number Of Immigrants</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Economics

BDSX

CRWD

GDOT

SPGC

SPHR

TNYA

US Futures Tumble As Traders Await Trump's Congress Address: 'Volatility Is Certainly Being Fed By Trump 2.0 Moves,' Says Expert

Citigroup analyst Patrick Donnelly upgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Sell to Neutral and raises the price target from $155 to $175.

Citigroup Upgrades Charles River to Neutral, Raises Price Target to $175

General

HYMTF

Hyundai Motor And Tate Announce Máret Ánne Sara As Next Hyundai Commission Artist

RDWR

Radware To Hold Its Hackers Challenge On March 13 In Peru

Citigroup analyst Anthony Pettinari initiates coverage on Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) with a Buy rating and announces Price Target of $19.

Initiation

TTAM

Citigroup Initiates Coverage On Titan America with Buy Rating, Announces Price Target of $19

FDA Approves TEVIMBRA In US For The First-Line Treatment Of Adults with Unresectable Or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Citigroup analyst Vikram Bagri initiates coverage on Centrus Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) with a Neutral rating and announces Price Target of $104.

Citigroup Initiates Coverage On Centrus Energy with Neutral Rating, Announces Price Target of $104

Biotech

Esperion Expects Full Year 2025 Operating Expenses Of $215M-$235M, Including Approximately $15M In Non-cash Expenses Related To Stock Compensation

Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.31 by 19.35 percent. This is a 7.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $11.66 million which beat the analyst consensus estimate of $11.39 million by 2.37 percent. This is a 5.09 percent decrease over sales of $12.29 million the same period last year.

Earnings Beats

Modiv Industrial Q4 AFFO $0.37 Beats $0.31 Estimate, Sales $11.66M Beat $11.39M Estimate

Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 78 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $69.11 million which beat the analyst consensus estimate of $61.58 million by 12.22 percent. This is a 114.30 percent increase over sales of $32.25 million the same period last year.

Esperion Therapeutics Q4 2024 GAAP EPS $(0.11) Beats $(0.16) Estimate, Sales $69.11M Beat $61.58M Estimate

Financing

Press Releases

LeddarTech Announces Receipt of the First Installment of the TI Pre-Paid Royalty Fee

LeddarTech to Host Investor and Business Update Call on December 18, 2024

LeddarTech Reports FY24 Results

LeddarTech Showcases LeddarVision Surround-View ADAS AI Platform Technology at CES 2025 in Las Vegas

LeddarTech Reports on Participation in CES 2025

LeddarTech Enters Into Amendments to Credit Facility and Bridge Financing Offer

Contracts

LeddarTech Announces First OEM Design Win for LeddarVision ADAS Solution

LeddarTech Announces Listing Transfer to the Nasdaq Capital Market; Comments on Recent Positive Business Developments

LeddarTech Reports Fiscal First Quarter 2025 Financial Results

Elevating Road Safety and Autonomous Driving: LeddarTech to Demonstrate Innovative Solutions at Three Key European Events

Comments

LeddarTech Holdings

Noticias

Últimas noticias sobre LeddarTech Holdings (NASDAQ:LDTC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL